Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at five years for… read more.
Gilead Sciences, Inc. announced that the FDA has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA)… read more.
Millions of Americans consume supplements that contain potentially hepatoxic botanical ingredients, according to a study from University of Michigan researchers. Over a 30-day period, 4.7% of the adults… read more.
As described in research published in the Biotechnology Journal, investigators have developed a novel patch that can help liver tissue regenerate. The patch is a combination of decellularized liver… read more.
Ipsen announced that the FDA has granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid… read more.
Bristol Myers Squibb announced the first presentation of results from the Phase III CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared… read more.
Bristol Myers Squibb announced the Phase III CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who… read more.
Mirum Pharmaceuticals, Inc. announced that Hepatology published an analysis demonstrating a statistically significant improvement in six-year event-free and transplant-free survival in patients with Alagille syndrome (ALGS) treated with… read more.
New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that treating rheumatoid arthritis with hydroxychloroquine (HCQ) reduced the risk of nonalcoholic fatty… read more.
Researchers from the University of Minnesota Medical School and College of Pharmacy have found that high costs for hepatic encephalopathy treatment in patients with end-stage liver disease were… read more.
Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the FDA approved Hepzato Kit (melphalan/Hepatic Delivery… read more.
Postmenopausal women who consume one or more sugar sweetened beverage daily appear to have a significantly higher risk of developing liver cancer and chronic liver disease than women… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
